Jered C. Garrison

3.2k total citations · 1 hit paper
71 papers, 2.8k citations indexed

About

Jered C. Garrison is a scholar working on Organic Chemistry, Inorganic Chemistry and Oncology. According to data from OpenAlex, Jered C. Garrison has authored 71 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Organic Chemistry, 18 papers in Inorganic Chemistry and 14 papers in Oncology. Recurrent topics in Jered C. Garrison's work include Radiopharmaceutical Chemistry and Applications (13 papers), N-Heterocyclic Carbenes in Organic and Inorganic Chemistry (11 papers) and Catalytic Cross-Coupling Reactions (10 papers). Jered C. Garrison is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (13 papers), N-Heterocyclic Carbenes in Organic and Inorganic Chemistry (11 papers) and Catalytic Cross-Coupling Reactions (10 papers). Jered C. Garrison collaborates with scholars based in United States, India and Iran. Jered C. Garrison's co-authors include Wiley J. Youngs, Claire A. Tessier, Richard S. Simons, Timothy J. Hoffman, Tammy L. Rold, Gary L. Sieckman, Said Daibes Figueroa, Matthew J. Panzner, Wei Fan and Wenting Zhang and has published in prestigious journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Jered C. Garrison

68 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ag(I) N-Heterocyclic Carbene Complexes: Synthesis, Structure, and Application

2005 988 citations Jered C. Garrison, Wiley J. Youngs profile →

Peers

Countries citing papers authored by Jered C. Garrison

Since Specialization

Citations

This map shows the geographic impact of Jered C. Garrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jered C. Garrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jered C. Garrison more than expected).

Fields of papers citing papers by Jered C. Garrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jered C. Garrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jered C. Garrison. The network helps show where Jered C. Garrison may publish in the future.

Co-authorship network of co-authors of Jered C. Garrison

This figure shows the co-authorship network connecting the top 25 collaborators of Jered C. Garrison. A scholar is included among the top collaborators of Jered C. Garrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jered C. Garrison. Jered C. Garrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploration of the utilization of irreversible cysteine protease inhibitor in FAP-targeted radiopharmaceuticals design to increase tumor residence time 2025 ·Nuclear Medicine and Biology ·(unknown), (unknown), (unknown), (unknown), (unknown), Jered C. Garrison	0
2	Enhanced Retention of NTSR1-Targeted Radionuclide Therapeutics via Covalent Inhibitors in Pancreatic, Colorectal, and Prostate Cancer Models 2025 ·Molecular Pharmaceutics ·Wenting Zhang, Wei Fan, (unknown), Alireza Basiri, (unknown), Lynette M. Smith, Subodh M. Lele, Abhijit Aithal, Maneesh Jain, Jered C. Garrison	0
3	Examination of Charge Modifications of an Endolysosomal Trapping Inhibitor in an Antagonistic NTSR1-Targeted Construct for Colon Cancer 2022 ·Bioconjugate Chemistry ·Wei Fan, (unknown), (unknown), Sameer Alshehri, (unknown), Cheng Zheng, Jered C. Garrison	3
4	Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors 2022 ·European Journal of Medicinal Chemistry ·Wei Fan, Wenting Zhang, Sameer Alshehri, Jered C. Garrison	2
5	Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy 2021 ·European Journal of Medicinal Chemistry ·(unknown), Sarbjit Singh, Jayapal Reddy Mallareddy, Yogesh A. Sonawane, (unknown), Sandeep Rana, Jacob I. Contreras, (unknown), Edward L. Ezell, Smitha Kizhake, Jered C. Garrison, Prakash Radhakrishnan, Amarnath Natarajan	13
6	Tricyclic Imidazolidin-4-ones by Witkop Oxidation of Tetrahydro-β-carbolines 2020 ·The Journal of Organic Chemistry ·(unknown), Yuxiang Dong, Jered C. Garrison, Xiaofang Wang, Edward L. Ezell, Douglas E. Stack, Jonathan L. Vennerstrom	8
7	In Vitro Evaluation and Biodistribution Studies of HPMA Copolymers Targeting the Gastrin Releasing Peptide Receptor in Prostate Cancer 2020 ·Pharmaceutical Research ·Sameer Alshehri, Wei Fan, Wenting Zhang, Jered C. Garrison	3
8	Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking 2019 ·Biomaterials ·Insiya Mukadam, Jatin Machhi, Jonathan Herskovitz, Mahmudul Hasan, Maxim Oleynikov, Wilson R. Blomberg, Denis Svechkarev, Aaron M. Mohs, You Zhou, Prasanta K. Dash, JoEllyn McMillan, Santhi Gorantla, Jered C. Garrison, Howard E. Gendelman, Bhavesh D. Kevadiya	22
9	Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonistic and Antagonistic Constructs 2019 ·Journal of Nuclear Medicine ·Wenting Zhang, Wei Fan, (unknown), Sameer Alshehri, Jered C. Garrison	12
10	1,2,3-Triazole–quinazolin-4(3H)-one conjugates: evolution of ergosterol inhibitor as anticandidal agent 2018 ·RSC Advances ·(unknown), Mohammad Irfan, Parvez Κhan, Mohamed F. Alajmi, Afzal Hussain, Jered C. Garrison, Md Tabish Rehman, Mohammad Abid	17
11	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities 2018 ·Biomaterials ·(unknown), (unknown), Wenting Zhang, Insiya Mukadam, (unknown), James R. Hilaire, Yutong Liu, JoEllyn McMillan, Benson Edagwa, R. Lee Mosley, Jered C. Garrison, Bhavesh D. Kevadiya, Howard E. Gendelman	27
12	Structure–Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors 2017 ·ACS Medicinal Chemistry Letters ·Yogesh A. Sonawane, Yingmin Zhu, Jered C. Garrison, Edward L. Ezell, Muhammad Zahid, Xiaodong Cheng, Amarnath Natarajan	20
13	Targeting Tumor Hypoxia in Radiotherapy: A Brief Review of Historical Background and Recent Progress 2016 ·Mutian Zhang, Zhengyuan Zhou, Zhihong Zhao, Jered C. Garrison, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	6
14	Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics 2015 ·Biomaterials ·Jinjin Zhang, Jered C. Garrison, Larisa Y. Poluektova, Tatiana K. Bronich, Natalia A. Osna	28
15	The influence of linker length on the properties of cathepsin S cleavable 177Lu-labeled HPMA copolymers for pancreatic cancer imaging 2014 ·Biomaterials ·Wen Shi, (unknown), (unknown), Zhengyuan Zhou, Yinnong Jia, Susan K. Brusnahan, Jered C. Garrison	17
16	177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable linkers: Synthesis, characterization and preliminary in vivo investigation in a pancreatic cancer model 2013 ·Nuclear Medicine and Biology ·(unknown), Wen Shi, (unknown), Zhengyuan Zhou, Susan K. Brusnahan, Jered C. Garrison	29
17	Evaluation of the Pharmacokinetic Effects of Various Linking Group Using the ¹¹¹In-DOTA-X-BBN(7−14)NH₂ Structural Paradigm in a Prostate Cancer Model 2008 ·Bioconjugate Chemistry ·Jered C. Garrison, Tammy L. Rold, Gary L. Sieckman, Farah Naz, (unknown), Said Daibes Figueroa, Wynn A. Volkert, Timothy J. Hoffman	49
18	Synthesis and characterization of a trigonal bipyramidal supramolecular cage based upon rhodium and platinum metal centers 2006 ·Chemical Communications ·Jered C. Garrison, Matthew J. Panzner, (unknown), D V S Reddy, Peter L. Rinaldi, Claire A. Tessier, Wiley J. Youngs	22
19	A fluorophenylboron-functionalized zirconium silsesquioxane complex 2004 ·Acta Crystallographica Section C Crystal Structure Communications ·Jered C. Garrison, Hoon Kim, Scott Collins, Wiley J. Youngs	1
20	2-Chlorophenyl 3-nitrobenzenesulfonate and 2,4-dichlorophenyl 3-nitrobenzenesulfonate: supramolecular aggregation through C–H...O, π–π and van der Waals interactions 2003 ·Acta Crystallographica Section C Crystal Structure Communications ·(unknown), (unknown), Semih Durmus, (unknown), Jered C. Garrison, Wiley J. Youngs	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact